Xilio Therapeutics, Inc. announced that on February 3, 2022, Rachel Humphrey, M.D. notified the Company of her decision to resign from the board of directors of the Company effective February 3, 2022. Following her resignation, Dr. Humphrey will serve as a consultant to the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.08 USD | -3.57% | -14.29% | +96.36% |
May. 14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.36% | 39.86M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.11% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Xilio Therapeutics, Inc. Announces Resignation of Rachel Humphrey from the Board of Directors